BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

While various clinical applications especially in oncology are now in progress such as
diagnosis, prognosis, therapy monitoring, or patient follow-up, the determination of structural …

The analysis of tumor-derived circulating cell-free DNA opens up new possibilities for
performing liquid biopsies for the assessment of solid tumors. Although its clinical potential …

Cell-free DNA (cfDNA) is a widely used noninvasive biomarker for diagnosis and prognosis
of multiple disease states. Emerging evidence suggests that cfDNA might not just be passive …

Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on
genomic alterations but have rarely considered the biological properties of plasma cell-free …

Objective To review clinical validation or implementation studies of maternal blood cell‐free
(cf) DNA analysis and define the performance of screening for fetal trisomies 21, 18 and 13 …

Cell-free DNA (cfDNA) in blood is used as a source of genetic material for noninvasive
prenatal and cancer diagnostic assays in clinical practice. Recently we have started a …

Liquid biopsy has been established as a powerful, minimally invasive, tool to detect clinically
actionable aberrations across numerous cancer types in real-time. With the development of …

The discovery of cell-free tumor and fetal DNA molecules in the plasma of cancer patients
and pregnant women, respectively, has opened up exciting opportunities in molecular …